US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports
May 16 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to tarlatamab, Amgen's targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported …